[1] Bekaert M, Verhelst X, Geerts A, et al. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev,2016,17: 68-80.
[2] Latronico MV, Condorelli G. Chemerin processing in the myocardium: A mechanism in search of a function. J Mol Cell Cardiol, 2016, 100: 21-24.
[3] Lin S, Teng J, Li J, et al. Association of Chemerin and Vascular Endothelial Growth Factor (VEGF) with Diabetic Nephropathy. Med Sci Monit, 2016, 22: 3209-3214.
[4] Andersson DP, Laurencikiene J, Acosta JR, et al. Circulating and Adipose Levels of Adipokines Associated With Insulin Sensitivity in Nonobese Subjects With Type 2 Diabetes. J Clin Endocrinol Metab, 2016, 101: 3765-3771.
[5] Wu QM, Ni HX, Lu X. Changes of adipocytokine expression after diabetic rats received sitagliptin and the molecular mechanism. Asian Pac J Trop Med, 2016, 9: 893-897.
[6] Takahashi M, Inomata S, Okimura Y, et al. Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism.Endocr J, 2013, 60: 37-44.
[7] Motamed N, Miresmail SJ, Rabiee B, et al. Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: A population based study. J Diabetes Complications, 2016, 30: 269-274.
[8] 张强,权兴苗,郑敏,等. 2型糖尿病及2型糖尿病合并非酒精性脂肪肝患者血清chemerin水平的变化.广东医学,2013,34: 1544-1547.
[9] Corona-Meraz FI, Navarro-Hernández RE, Ruíz-Quezada SL, et al. Inverse Relationship of the CMKLR1 Relative Expression and Chemerin Serum Levels in Obesity with Dysmetabolic Phenotype and Insulin Resistance. Mediators Inflamm, 2016,2016: 3085390.
[10] Zhuang X, Sun F, Li L, et al. Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Clin Lab, 2015, 61: 1409-1414. |
